IL6 and cancer: Cancers cells can reprogram adipocyte physiology leading to an “activated” phenotype characterized by delipidation and secretion of inflammatory adipokines such as IL-6, leptin and fatty acids which are able to change cancer cell metabolism and signalling pathways to promote tumour progression (Dumas and Brisson 2021).